Online controlled experiments, also called A/B testing, have been established as the mantra for data-driven decision making in many web-facing companies. A/B Testing support decision making by directly comparing two variants at a time. It can be used for comparison between (1) two candidate treatments and (2) a candidate treatment and an established control. In practice, one typically runs an experiment with multiple treatments together with a control to make decision for both purposes simultaneously. This is known to have two issues. First, having multiple treatments increases false positives due to multiple comparison. Second, the selection process causes an upward bias in estimated effect size of the best observed treatment. To overcome these two issues, a two stage process is recommended, in which we select the best treatment from the first screening stage and then run the same experiment with only the selected best treatment and the control in the validation stage. Traditional application of this two-stage design often focus only on results from the second stage. In this paper, we propose a general methodology for combining the first screening stage data together with validation stage data for more sensitive hypothesis testing and more accurate point estimation of the treatment effect. Our method is widely applicable to existing online controlled experimentation systems.
INTRODUCTION
Controlled experiments have been used in many scientific fields as the gold standard for causal inference, even though only in the recent decade has it been introduced to online services development (Christian 2012; Kohavi et al. 2009; Manzi 2012) where it gained the name A/B testing. At Microsoft Bing, we test everything via controlled experiments, including UX design, backend ranking, site performance and monetization. Hundreds of experiments are running on a daily basis. At any time, a visitor to Bing participates in fifteen or more concurrent experiments, and can be assigned to one of billions of possible treatment combinations .
Surprisingly, the majority of the current A/B testing literature focuses on single stage A/B testing, where one experiment (with one or more treatments) is conducted and analyzed at a time. A likely cause could be that A/B testing is traditionally conducted at the end of a feature development cycle, to make final feature ship decision and measure feature impact on key metrics. As A/B testing gains more recognition as one of the most effective sources of data-driven decision making, and with scaling of our experimentation platform, A/B testing is now employed earlier in feature development cycles. Thus comes the need for multiple stages of experiment, in which the results of an earlier screening stage can inform the design of a later validation stage. For example, when there are multiple shipping candidates, we design the screening stage experiment to select the most promising one. If such a best candidate exists, we conduct a second validation run to make final ship decision and measure treatment effect. This type of two stage experiments with treatment selection and validation is commonly used in practice. The space of treatment candidates ranges from 2 to 5 or even 10 in the screening stage. When candidate number exceeds 10, we can aggressively sift candidates via offline measurement or "paired test" such as interleaving (Radlinski and Craswell 2013) to boost statistical power in the data analysis.
In this paper, we focus on statistical inference in this two-stage design with treatment selection and validation. The validation stage involves only winner from the screening stage and a control. It is analyzed in the traditional A/B testing framework and is well-understood (Section 2.1). The first screening stage, however, includes simultaneous analysis of multiple treatments. We need to adjust hypothesis testing procedure to control for inflated false positives in multiple comparison (Section 2.2). We improve on traditional adjustments such as Bonferroni and Holm's method (Holm 1979) , as they are typically too conservative. In Section 3 we propose a sharp adjustment method that is exact in the sense that it touches the claimed Type I error. Point estimation is also nontrivial as the treatment selection introduces an upward bias (Lemma 4). One might wonder why this is important since in A/B testing people are generally only interested in finding the best candidate to ship. We found in a data driven organization it is equally crucial to keep accurate records of impacts made by each individual feature. These records help us understand the return on investment, and prioritize development to benefit users/customers. In Section 4 we propose several methods to correct the bias and investigate more efficient estimators by combining data from both stages. In Section 2.3, we show an insightful theoretical result to ensure we can almost always treat the treatment effect estimates from two stages as independent, given treatment procedures which assign independently, despite overlap of experiment subjects in the two stages. With this result, we propose our complete recipe of hypothesis testing in Section 3 and several options for point estimation in Section 4.
To the knowledge of the authors, this is the first paper in the context of online controlled experiments that studies the statistical inference for two-stage experiment with treatment selection and validation. This framework can be widely usable in existing online A/B testing systems. Key contributions of our work include:
• A theoretic proof showing negligible correlation between treatment effect estimates from two stages, given the treatment assignment procedure in the two stages are independent, which is generally useful in theoretical development for all multi-staged experiments. • A more sensitive hypothesis testing procedure that correctly adjusts for multiple comparison and utilized data from both stages. • Several novel bias correction methods to correct the upward bias from the treatment selection, and their comparison in terms of bias and variance trade-off. • Demonstration from empirical evidence that we get more sensitive hypothesis test and more accurate point estimates by combining data from both stages.
BACKGROUND AND WEAK DEPEND-ENCE BETWEEN ESTIMATES IN TWO STAGES
Before diving into two-stage model, we first briefly cover the analysis of one stage test. Here we follow the notation in ).
Treatment vs. Control in One Stage A/B Test
We focus on the case of the two-sample t-test (Student 1908; Wasserman 2003) . Suppose we are interested in a metric X (e.g. Clicks per user). Assuming the observed values of the metric for users in the treatment and control are independent realizations of random variables X (t) for treatment and X (c) for control respectively, we can apply the t-test to determine if the difference between the two groups is statistically significant. Under the random user effect model, for user i in control group,
where µ is the mean of X (c) , αi represents user random effect and ǫi is random noise. Random user effect α has mean 0 and variance Var(α). Residual E[ǫ|α] = 0. The random pair (αi, ǫi) are i.i.d. for all user. However, we don't assume independence of ǫi and αi, as the distribution of ǫ might depend on α, e.g. users who click more might also have larger random variation in their clicks. However ǫi and αi are uncorrelated by construction since E(ǫα) = E[E(ǫ|α)] = 0. For treatment group,
where fixed treatment effect θ can vary from user to user but θ is uncorrelated to the noise ǫ. The average treatment effect (ATE) is defined as the expectation of θ. The null hypothesis is that δ := E(θ) = 0 and the alternative is that it is not 0 for a two-sided test. For one-sided test, the alternative is δ ≤ 0 (looking for positive change) or δ ≥ 0 (looking for negative change). The t-test is based on the t-statistic:
where observed difference between treatment and control ∆ = X (t) − X (c) is an unbiased estimator for the shift of the mean and the t-statistic is a normalized version of that estimator. In traditional t-test (Student 1908), one needs to assume equal variance and normality of X (t) and X (c) . In practice, the equal variance assumption can be relaxed by using Welch's t-test (Welch 1947) . For online experiments with the sample sizes for both control and treatment at least in the thousands, even the normality assumption on X is usually unnecessary. To see that, by central limit theorem, X (t) and X (c) are both asymptotically normal as the sample size m and n for treatment and control increases. ∆ is therefore approximately normal with variance
The t-statistics (2) is approximately standard normal so ttest in large sample case is equivalent to z-test. The central limit theorem only assumes finite variance which almost always applies in online experimentation. The speed of convergence to normal can be quantified by using Berry-Essen theorem (DasGupta 2008). We have verified that most metrics we tested in Bing are well approximated by normal distribution in experiments with thousands of samples.
Multiple Treatments in A/B Test
When there is only one treatment compared to a control, ∆ is both the Maximum likelihood estimator (MLE) of the treatment effect, and an unbiased estimator. When there are multiple treatments and we observe ∆ (j) for the jth treatment, it can be shown that max(∆ (j) ) is MLE of max(δ (j) ), where δ (j) is the true underlying treatment effect of the jth treatment. However, it is obvious that max(∆ (j) ) is no longer an unbiased estimator. To see this, assuming δ (j) = 0 for all j, the distributions of ∆ (j) 's are symmetric around mean 0. But the distribution of max(∆ (j) ) will certainly be skewed to the positive side and with a positive mean. Note that max(δ (j) ) = 0. max(∆ (j) ) will have a upward bias. Furthermore, Lemma 4 in Appendix showed that if pth treatment is selected (p is random as it is picked as the best treatment), ∆ (p) = max(∆ (j) ) is not an unbiased estimator for δ (p) . 1 Section 4 introduces a novel method to correct bias so we can achieve a estimator of δ (p) with smaller mean squared error (MSE).
Besides point estimation, hypothesis testing in experiments with multiple treatments also suffers from an issue called multiple comparison (Benjamini 2010) . Framework of hypothesis testing only guarantees Type I error (False Positive Rate) be controlled under the significant size, which is usually set to 5%, when there is only one test. When there are multiple comparisons, and if we are looking for the "best" treatment among all the treatments, our chance of finding false positive increases. If we have 100 treatments, all have 0 true treatment effect, we still expect to see on average 5 out of 100 of them showing a p-value below 0.05 just by chance. To deal with this, various of p-value adjustment techniques have been proposed, such as Bonferroni correction, Holm's method (Holm 1979) and false discovery rate based methods suitable for even larger number of simultaneous comparisons (Benjamini and Hochberg 1995; Efron 2010) . Both Bonferroni and Holm's method are applicable to the general case with unknown covariance structure between test statistics of all comparisons. In the context of online A/B testing, when we have large samples, we live in a simpler multivariate normal world. We have full knowledge of the covariance structure of this multivariate normal distribution and we should be able to exploit it to come up with a better hypothesis testing procedure. Section 3 contains more details.
Weak Dependence
When we combine results from two stages to form a more sensitive test and estimate treatment effect more accurately, one of the challenges we face is caused by possible dependence of the observed metric values from the two stages. In theory we may force independence between the two stages by running them on separate traffic, so the two stages share no users in in common. This is undesirable in any scaled A/B testing platform ) because 1. It means the total traffic in both stages combined cannot exceed 100%, and we suffer from decreased statistical power in both stages. 2. It requires additional infrastructure to ensure no overlap in traffic between the two stages, which can pose technical challenges when we run multiple experiments at the same time. In this section, we explain why in practice we can safely assume independence between the observed ∆ from two stages, as long as the randomization procedure used in the two stages are independent. For online A/B testing, randomization is usually achieved via bucket assignment. Each randomization id, e.g. user id, is transformed into a number between 0 to K − 1 through a hash function and modulo operation. Independent randomization procedures between any two experiments can be achieved either by using different hashing functions and re-shuffle all K buckets, or 1 There is a sutble difference between the two scenarios. In the former case we use max(∆ (j) ) to estimate the best treatment effect max(δ (j) ) and in the latter case we only want to estimate the treatment effect of pth treatment without worrying about whether it is truly the best treatment effect.
preferably, via localized re-randomization described in Kohavi et al. (2012, Section 3.5) .
For the same experiment that has been run twice in the two stages, we model user random effect to be the same for the same user in both stages, but the random noises are independent for different stages. In particular, for a pair of measurement from the same user (Xi, Yi),
where ǫi and ζi are noise for each run. ǫi and ζi are independent and all random variables with different index i are independent. We allow µ (1) to be different from µ (2) to reflect a change in mean due to some small seasonal effect. After exposure to a treatment, there is an additional treatment effect term θi in
where θ is uncorrelated to both noise ǫ and ζ.
We are now ready for the first result of this paper. Let N be the total number of users that is available for online A/B testing. For the screening run, we picked m users as treatment and n as control. For the second run, we picked m ′ users for treatment and n ′ for control. If the random user picking for the two runs are independent of each other, let ∆1 and ∆2 be the observed difference between treatment and control in the two runs, then Theorem 1 (Almost Uncorrelated Deltas). Assuming independent treatment assignment, we have
This holds whether m, n, m ′ , n ′ are random variables or deterministic.
To understand why Theorem 1 holds, remember N is the total user size available for experimentation, θ is the treatment effect. Also, Var(∆1) = Var(X (t) )/m + Var(X (c) )/n and similarly Var(∆2) = Var(Y (t) )/m ′ + Var(Y (c) )/n ′ . We are interested in the correlation defined by
If the percentage average treatment effect is d%, then we argue that Var(θ)/Var(X) is roughly (d%) 2 . To see this, if treatment effect is a fixed multiplicative effect, i.e. θ/X = d%, we have Var(θ) = d% 2 Var(X). Var(θ)/Var(X) is at the scale of (d%) 2 for any reasonable treatment effect model. Since N is always larger than m, n, m ′ , n ′ , by (3), we know Corr(∆1, ∆2) ≤ (d%) 2 . In practice, most online A/B testing has a treatment effect less than 10% (In fact a 1% change is quite rare for many key metrics. If the treatment effect is more than 10%, then by the volume of traffic online experiment can cheaply gather, detecting such a large effect is usually easy and experimenters don't need to rely on combining results from multiple stages to increase the power of the test.) This means Corr(∆1, ∆2) ≤ 0.01 for almost all experiments we care about in practice, and Corr(∆1, ∆2) ≤ 10 −4 among most of the cases.
What does this result entail? Remember in our large sample setting, ∆1 and ∆2 are approximately normal. For normal distribution, no correlation is equivalent to independence. The result from the above discussion tells us that in almost all interesting cases, we can safely treat ∆1 and ∆2 as if they are independent. In two-stage A/B testing with treatment selection and validation, the screening stage involves multiple treatments. A straightforward extension of Theorem 1 shows the vector of observed ∆'s ∆1 and ∆2 has negligible correlation, hence are almost independent. Furthermore, for hypothesis testing purpose (Section 3), under null hypothesis, we assume there is no treatment effect. Hence we know correlation between ∆ from two stages would be less than (d%) 2 , thanks to Theorem 1, which is 0.
We make our final remark to close this section. In the model we assumed the user effect α and the treatment effect θ for two runs of the same experiment to be the same for the same user. This can also be relaxed to allow both user effect and treatment effect for the same user in two runs to be a bivariate pair with arbitrary covariance structure. Theorem 1 still holds if we change Var(θ) in (3) to covariance of the treatment effect.
HYPOTHESIS TESTING
In statistics, combining results from different studies is the subject of a field called meta-analysis. In this section we present a method for hypothesis testing utilizing data from both stages. Using combined data for point estimation is discussed in Section 4.
Meta-Analysis: Combine Data from Two Stages
Suppose we conduct two independent hypothesis tests and observed two p-values p1 and p2. A straightforward attempt of combing two "probability of falsely rejecting null hypothesis" would be to multiply the two p-values together, and claim the product p = p1 × p2 to be the p-value of the combined test. This seemingly sound approach actually produce p-values smaller than the true Type I error. To see this, under null hypothesis, p-values p1 and p2 follow the uniform(0,1) distribution. Type I error of combined test is P(U1 × U2 ≤ p) where U1 and U2 are two independent uniform(0,1) distributed random variables. This probability can be calculated using a double integral:
Since p < 1, Type I error p(1 − log p) > p. The underestimation of Type I error could be very significant for common p-values. When p = p1 × p2 = 0.1, the true Type I error if we reject the null hypothesis would be 3.3×0.1, meaning the true Type I error is underestimated by more than 3 times if we simply multiply the two p-values. Equation (4) provides the correct p-value calculation theoretically. To use it in hypothesis testing for usual p-value cutoff at 0.05, the product p required to make p(1 − log p) ≤ 0.05 is 0.0087.
The calculation of true Type I error when multiplying more than 2 p-values quickly becomes cumbersome. Fisher (Fisher et al. 1970 ) noticed natural log function transforms uniform(0,1) distribution into an exponential(1) distribution and exponential (1) is half of a χ 2 with 2 degrees of freedom. In this connection, the product of k p-values under null hypothesis is sum of independent exponential(1) and
This result, known as the Fisher's method, can be used to combine tests under the assumption of independent pvalues. It is also a model-free method in the sense that it only utilizes p-value without tapping into the distribution of test statistics. It is not surprising that in our cases, by using normality and known covariance structure of our observed ∆'s, we should be able to get a more sensitive test. We leave this extension in Section 3.2. However, we still have the multiple comparison issue to tackle. One standard method is Bonferroni correction. Specifically, 1. First we determine the p-value from the screening stage using a Bonferronni correction. If there is K treatment candidates in the screening run, if p1 the smallest pvalue, we just divide this p-value by K.
2. We use this value plus the p-value for the second stage and combine using Fisher's method.
This combined with Fisher's method provides a valid hypothesis testing for two-stage A/B testing with treatment selection and validation. We will just call it BF method and set it as our benchmark.
Sharp Multiple Comparison Adjustment
In this section we improve BF method in two directions. We will use a sharper multiple comparison adjustment. We also exploit known distribution properties to form a test statistic. We call our method generalized weighed average method since the test statistic is in a form of weighted average.
Although Bonferroni correction is the simplest and most widely used multiple comparison adjustment, it is often too conservative in online controlled experiments. This is because by central limit theorem, we can safely assume all metrics to be approximately normal. More specifically, let X1, X2, . . . , X k be the observed metric values (e.g. clicks per user) for the k treatments and X0 be the value for the control, we can estimate the variance of each and take these as known in our model. Moreover, the covariance between ∆i, i = 1, . . . , k can also be estimated. In this scenario of complete distributional information, we can use a generalized step-down procedure (Romano 2005, Section 9.1, p.352).
Generalized step-down procedure
Given observed ∆1, . . . , ∆ k , we first test against the null hypothesis that all treatments are no greater than 0. In the screening stage we assign equal traffic size for all treatments. We use max(∆i) as the test statistics. ∆1, . . . , ∆ k follows a multivariate normal distribution with known covariance matrix. We can theoretically compute the distribution of max(∆i) under the least favorable null hypothesis, which is when all treatment effects are 0 (Toothaker 1993, Appendix 3, p.374). In practice, we resort to Monte Carlo simulation. We simulate B i.i.d random samples from multivariate normal distribution with mean 0 and the estimated covariance matrix. For each trial we record the max(∆i). The simulated B data points serve as an empirical null distribution of max(∆i). A p-value can then be calculated using the empirical distribution. The step-down procedure rejects the null hypothesis for the treatment with the largest ∆. Then it take the remaining ∆'s and continue the same test against the null hypothesis for this subset of treatments. This procedure stops when the test fails to reject the subset null hypothesis and it accepts them all. It can be proved that this procedure, like Bonferroni correction, controls the family-wise false positive rate. But it is strictly less conservative than Bonferroni correction. A two-sided test would be looking at the extreme value, i.e. max(abs(∆i)) with otherwise the same procedure.
For our purpose of testing two-stage experiments with treatment selection and validation, we can stop at the first step, since we only care about the selected treatment with the largest ∆ at the screening stage. How do we combine this with the validation stage ∆? If there are no multiple treatments at the screening stage, we are just replicating the same experiment twice. Thanks to Theorem 1, we can treat the two ∆'s as independent. Then any weighted average of the two would be an unbiased estimator for the underlying treatment effect. We define
where ∆ (1) and ∆ (2) stands for the observed ∆ in two stages respectively. To minimize the variance of this unbiased estimator, the optimal weight w would be proportional to 1/Var(∆ (s) ), s = 1, 2. This combined test statistics is also normally distributed, and therefore can be standardized into a Z-score. We call it combined Z-score method.
Generalized weighted average test
To adopt combined Z-score test to support treatment selection in the screening stage, we modify the test statistics as:
where ∆ * is the observed ∆ at the validation stage for the selected treatment form the screening stage. The optimal weight can also be estimated, by calculating Var(max(∆i)) theoretically or from simulation. We then form empirical null distribution through simulation with this test statistic, and calculate p-values. This method is in spirit the same as the combined Z-score, just with an adjustment to the null distribution.
This generalized weighted average test is more favorable comparing to more generic methods such as BF method. It exploits the know distributional information otherwise ignored. It is sharp in the sense that it would touch the designated Type I error bound, unlike BF method. The reason is, it does not rely on loose probability inequalities such as Bonferroni inequality, which was required to control for Type I error for all forms of tests. Instead it relies on simulation to get the exact Type I error, no more, no less. The weighted average method combines the data from two stages nicely and optimally. We compare generalized weighted average test to BF method in Section 5.1. The same idea of using weighted average will also be used in Section 4 for point estimation of the treatment effect.
POINT ESTIMATION
Another task for A/B testing is to provide good estimation of the true treatment effects, in terms of minimal meansquared error (MSE) that achieves a balance between bias and variance.
In the screening stage of the experiment, suppose we have k different treatments with metric values X1, . . . , X k respectively. Thanks to the central limit theorem, we can assume X = (X1, X2, . . . , X k ) T ∼ N (µ, Σ) where µ = (µ1, . . . , µ k ) T and Σ = diag(σ 2 1 , . . . , σ 2 k ) 2 . Moreover, there is a control group with the metric value X0 ∼ N (µ0, σ 2 0 ). The estimation of σi is easy to achieve with a large sample and of no interest in this paper, thus we assume the variances are known and fixed. Without loss of generality, assume σ = σ0 = · · · = σ k . Then we can use ∆i = Xi − X0 as the estimation of the effect of the ith treatment. At the end of the screening stage, we choose the treatment with the largest ∆ by maxi = argmax i ∆i = argmax i Xi, then run the second-stage experiment with only the control group and the maxith treatment.
In the validation stage, X * maxi ∼ N (µmaxi, σ ′2 ) for the selected treatment is obtained, as well as the new observation for control group X * 0 ∼ N (µ0, σ ′2 ). Let ∆ * maxi = X * maxi − X * 0 . According to Theorem 1, we can ignore the dependence between the observed ∆'s from the two stages.
To estimate the true treatment effect δ = µmaxi − µ0, ∆ * maxi is the MLE and also is unbiased thus optimal for the validation stage. However, according to Lemma 4, ∆maxi is actually upward biased. Thus a traditional choice for the point estimation is only by ∆ * maxi . The MSE for this estimator is σ 2 . It is clear that this method is less efficient as we ignore the useful information from the screening stage. Denote∆maxi as the estimation in the screening stage. For weighted averageδw = w ·δmaxi + (1 − w) · ∆ * maxi :
The best w that minimizes the MSE can be found by solving
MSE(∆ maxi ) . In practice, even by a naive choice of w = 1/2, we are guaranteed to have a better MSE if MSE(δmaxi) < 3σ 2 . Thus the task in this section is to find a good estimatorδmaxi for the screening stage, or equivalently, a good estimatorμmaxi for µmaxi, as we can always let δmaxi =μmaxi − X0. X0 is independent of Xi, i = 1, . . . , k and does not suffer from the selection bias, and it is also optimal for µ0.
Letμmaxi,MLE be the estimator for Xmaxi. Define the bias of MLE as λ(µ) = Eµ(Xmaxi − µmaxi). λ(µ) is positive as shown in Lemma 4. So we seek a bias correction for λ(µ), and propose the following estimators: 2 Usually the metric X is in a form of average. We use X here to simplify the notation. Metric can also be a ratio of averages, such as Clicks Per Query. For this kind of metric, vector of numerator and denominator follows a bivariate normal distribution under central limit theorem with known covariance structure. We can then use the delta method to calculate variance of the metric.
Naive-correction estimator
Based on the screening stage observation X = x, simulate B independent y b ∼ N (x, σ 2 I). Calculate the expected bias λ from the simulated samples. Then useμmaxi,naive = Xmaxi −λ as the estimator. Note that this is actually a "plug-in" estimation asλ(µ) = λ(x). Denote this estimator asμmaxi,naive. Compared toμmaxi,MLE, the naive-correction has smaller bias but larger variance.
Var(μmaxi,naive) = Var(μmaxi,MLE) + Var(λ(X)) − 2Cov(μmaxi,MLE, λ(X)) in which Cov(μmaxi,MLE, λ(X)) can be expected to be negative. This makesμmaxi,naive inferior when the true estimation bias ofμmaxi,MLE is small, as can be seen from simulation results in Section 5.2. The slight bias in the naivecorrection is immaterial for the performance according to our evaluation.
Inspired by the drawback of the naive-correction, we seek some simpler factor that could account for the major factor but with a smaller variance. Apparently the gap between the largest µi and the second largest µi can be a major factor for the bias. However, µ is unknown so an alternative with similar information is needed. Assume X (1) , X (2) ...X (k) are the order statistics. Define the first order gap as H(X) =
, then bias λ(µ) is roughly monotonic with the average observed H(X). Thus H can be seen as a major factor for the bias in the sense of expectation. Such relationship can be observed in Figure 1 , which is produced by 2000 randomly sampled µ's as described in Section 5.2. Similarly, one can define higher order gap such as the ith order gap as Hi(X) =
and try to fit λ(µ) beyond univariate function. 
by linear models. We recommend using natural cubic splines (cubic splines with linear constraints outside boundary knots) for the model. Take the expected biasλ as the model prediction on H(x) and useμmaxi = xmaxi −λ+ as the estimation. Call this NS estimation. Simulation shows that its performance is robust against the choice of the exact linear form. For instance, using cubic polynomial regression would achieve similar performance according to our evaluation. The intuition behind the simulation in NS is that suppose we can can simulate from N (µ, σ 2 I), then we should be able to have a very good recovery of λ ∼ f (H(µ) ). However since we don't know µ, we need a reasonable population is by generating random samples in a similar way as how we get X.
In NS, we use a "plug-in" population to simulate the data we need.
Bayesian posterior driven linear-correction estimator
Since the naive correction based on MLE suffers from high variance, we try Bayesian approach to avoid over-fitting the data for a low variance estimator. Assume a prior µ ∼ N (0, τ 2 I) 3 . Here we take an empirical Bayes approach to construct the posterior mean and variance as shown in (Efron and Morris 1973) -the posterior mean turns out to be the famous James-Stein estimator (Stein 1956; James and Stein 1961) . Then the formula becomes
When the shrinkage (1 − (k−2)σ 2 X 2 2 ) ≤ 0, we take it as zero and it becomes a posterior as P (µ = 0) = 1. We call the posterior constructed in this way JS posterior. This gives another estimator: for b = 1, . . . , B, we first sample µ b from the JS posterior, and then sample y b ∼ N (µ b , σ 2 I). All the remaining modeling steps are the same as NS. We call this JS-NS estimation. Intuitively, compared to NS, JS-NS uses hierarchical sampling based on a shrinkage estimation by using an empirical Bayesian prior which is expected to make the model fitting more robust, thus giving a lower variance. Nevertheless, since the posterior shrinks the estimation toward 0, JS-NS estimate the bias well when true treatment effects are close to 0 but can over-correct the bias when bias is small. We see JS-NS as a further step beyound NS to lower variance by allowing for some remaining biases. See Efron (2011) for another application of Empirical Bayes based selection bias correction. Beyond simple linear-correction One can further explore more sophisticated (multivariate and non-linear) modeling under the logic of linear-correction.
A few examples are included for completeness in Section 5.2. However, we observe no significant gains.
We can set a large number B of simulation trials to fit the functional form (6), as the computation is simple and fast. We observed that beyond B > 10000, more runs no longer make much difference. For the natural cubic splines, one can simply choose the simple version by using 3 knots. It turns out that the NS estimator with this setting achieved the best compromise between the bias and variance out of the candidates, which will be illustrated in more details in the Section 5.2. In practice, when using weighted average to combine this estimator with the second validation stage MLE, we don't know the MSE of the estimator and therefore can not get the optimal weight. However, it is reasonable to use weights inverse proportional to the sample size in formula (5), i.e. assume MSE of the two estimators in two stages are the same for the same sample size.
EMPIRICAL RESULTS

Empirical Results for Hypothesis Testing
In this section we use simulation to compare the BF method to the generalized weighed average method. To simulate the two-stage controlled experiments with treatment selection and validation, we assume a pair of measurement from the same user comes from a bivariate normal distribution with pairwise correlation coefficient ρ = 0.5 between stages, and variance 1. The choice of the variance 1 here is irrelevant because one can always scale a distribution to unit variance. The correlation coefficient here is also less important. Also note that the specific distribution of this user level measurement is not very important because of the central limit theorem. For treatment effect, we set a treatment effect on each user using a normal distribution N (θ, σ 2 θ ). For each run of experiment, we randomly generated N = 1000 pairs of such samples from the bi-variate normal distribution, representing 1000 users entering into the two stages of the experiment. In each run we randomly assign equal proportions to be treatments and control respectively. In the screening stage, there are k = 4 treatment candidates and we select the best one to run the validation stage. In the context of Theorem 1, this means m = n = N/5 and m ′ = n ′ = N/2. The random sampling for the two runs are independent.
Type I error under the null hypothesis
We study Type I error achieved by BF method and generalized weighted average method under the least favorable null where all treatment effects are 0. We seek positive treatment effects as our alternative hypothesis. For two stage experiments, when validation run shows a ∆ that is in different direction comparing to the screening stage run, it generally means the findings in the screening stage cannot be replicated and it then make less sense trying to combine the two runs. Therefore, when either of the twoδ were negative, we set pvalues to 1.
We ran 10, 000 simulation trials to show Type I error under null hypothesis where all treatment effects are 0. It confirms our claim that BF method is too conservative, with a 3.2% true Type I error. On the other hand, our generalized weighted average approach (WAvg), at 5.1% closely touches the 5% Type I error as promised.
We then assess the impact of the small correlation in Theorem 1 that was ignored when we performed the test. Although under the least favorable null hypothesis, treatment effects are all 0 and the correlation is exactly 0, we can still relax the null hypothesis and add some variance in the random user treatment effect θ. To do that, we assume even though E(θ) = 0, but Var(θ) = 0.04. Since we set the variance of user level measurement to be 1, this setting means the random treatment effect has a standard deviation of 20% of that of the user level measurement. As we discussed, a 10% treatment effect is already already very rare for online A/B testing, needless to mention 20%. To test the robustness of the test against the impact of the correlation between the two stages, we ran another 10, 000 trials when treatment effect has a 20% standard deviation and observe the same phenomenon. BF method has a 3.3% true Type I error while WAvg still achieves 5.0%.We see that both generalized weighted average and BF method are very robust. This empirically justifies Theorem 1 that we can safely ignore the small correlation between the two stages. However, Theorem 1 also shows as the variance of user random treatment effect Var(θ) gets larger, the correlation could be significant. As an extreme case, we did the same simulation for Var(θ) = 1, i.e., treatment random effect has the same standard deviation as the measurement itself. We found the Type I error of generalized weighted average method increased to 12.3% while for BF method it stayed at 4.2%. This suggests BF method might be more robust against the correlation than generalized weighted average method.
Statistical power under the alternative hypothesis
Next we compare the sensitivity of the two tests under alternative. We increase N to 110, 000 and let the treatment effect vary from 0 to 0.03 with step size 0.001. We also increased the number of treatments to 10 and set the same treatment effect on them. Figure 2 shows the power curve estimated from 10000 simulation runs. We observed that BF method could be inferior to validation run t-test for small treatment effects, even though it tried to take advantage of data from the screening run. By contrast, generalized weighted average method had higher power than both of them for the whole range, with a gap of 10% to 15% for the middle range. When µ = 0.015, power for weighted average method was 81% and the power for BF and validation run t-test was only at around 68%. Hence we've seen generalized weighted average method is more sensitive. To evaluate the proposed estimators of µmaxi, we simulated 200 experiments with four treatments each, their means µ from N (η, 4I), where η = (2, 2, 2, 2) T is irrelevant to the estimation. Without loss of generality, we use σ = 1 in simulation. Then for each experiment, we generated 1500 independent random vectors x with mean µ, and calculated their MSE Note we can only observe one x in practice. In all the estimations, the B is chosen to be 10000. The knots for splines were chosen as the (0.1,0.5, 0.9) quantiles of the simulated H(y b ).
Three additional methods were included for completeness: the bi-variate natural splines estimation and boosted trees with two variables for bias correction via H(X) and H2(X). The bi-variate splines model is an example of including more predictors: setting the basis functions with 6 degree of freedom for both of the two variates without any interaction term. We label this estimator NS-2 and the corresponding univariate version as NS-1. The boosted trees can be seen as an example when one seeks to model the bias exhaustively by using the two predictors (but still in a regularized way). In each estimation of equation 6, all base trees were required to be of depth 3 (so at most 2 orders of interaction will be considered in each base learner), and 1200 trees were trained in each estimation, with final prediction model selected according to hold-out squared prediction error. We label this estimator as Boost. The last estimator is a mixture between MLE and JS-NS according to the rule: if H(X) > 1 take MLE as the estimator and otherwise use JS-NS. The intuition behind this will be explained in Remark 1. We label it as MLE-JSNS-Mixture. Many threshold values other than 1 were evaluated as well but they all suffer from the same problem which will be discussed later.
In addition to MSE, the bias and variance of each estimators were also studied respectively. For the clearness of illustration, only 16 µ's are shown in detail below, with error bars for the MSE and biases estimated by 1500 instantiations. These 16 µ are representative for the general case according to our observations. The error bars of the variance are too small to be shown, thus were ignored. The 16 µ's are ordered according to the first order gap H(µ). In each figure, they are also split into two groups: the ones with H(µ) > 1 and those with H(µ) < 1. Figure 3 shows that MLE has smaller bias and larger variance when H(µ) is large and vice versa. When the true bias is small, the naive correction become inferior to MLE while in other cases, it achieves much smaller MSE. Figure 4 shows that naive-correction results in minimum bias on average, but has large variance. Thus it will be outperformed by MLE when the gain in bias is small. On the other hand, NS-1 achieved a good compromise between the two. It performs nearly as good as naive-correction when naive-correction works well, while still retains reasonably good MSE when the naive-correction fails. Neither NS-2 nor Boost seems to improve the performance. Thus using the univariate linear estimator is the best choice among the candidates. JS-NS performs significantly better than others in the case of H(µ) < 1, and closely to NS for moderate H(µ). Figure 4 reveals the advantage of JS-NS. The variance of JS-NS is always similar to MLE, much lower than all other variables. This means using hierarchical sampling with JS posterior does help to make the estimation stable. As discussed before, JS tends to over-correct the bias when H(µ) is large though as shown in the bias plot. In summary, JS-NS is the best one in most cases while NS is a good choice if one conservatively prefers a good performance uniformly.
Remark 1. Figure 3 indicates a simple rule of selecting correction method: if H(µ) is large, use MLE, otherwise use correction estimation (for instance, JS-NS). Since µ is unknown in practice, one alternative is to use observed H(X) instead. This is the intuition for MLE-JSNS-Mixture and its variants. However, it turns out that these estimators perform poorly in many cases due to the large variances as shown in Figure 4 , though the biases are small. Using H(X) > 1 introduces extra variance that degraded performance of the estimators. H(µ) is large, all candidates except MLE have higher MSE than σ 2 . Such extra MSE is the price we have to pay for not knowing the oracle of whether we need bias correction beforehand. In the best cases, the MSE of the final estimation is lower than σ 2 , even better than the case of single random variable. This is an effect of "learning from the experience of others" discussed in Efron (2010) . That is, since µi's are close in such cases, knowing all xi's could help to improve the estimation. H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H<1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 H>1 
Remark 2. When
CONCLUSION
When data-driven decision making via online controlled experiment becomes a culture and the scale of an online A/B testing platform reaches a point when anyone can and should run their ideas through A/B testing, it is almost certain that A/B testing will eventually be employed through the full cycle of web-facing software developments. This is already happening now at Microsoft Bing. In this paper, we took our first steps to build the theoretical foundation for one of the multi-stage designs that is already a common practice -two-stage A/B testing with treatment selection and validation.
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